From: Soluble receptor for advanced glycation end-products and progression of airway disease
All | Non-smokers | Smokers without COPD | Smokers with COPD | |||||
---|---|---|---|---|---|---|---|---|
(n = 295) | (n = 32) | (n = 212) | (n = 51) | |||||
r | p-value | r | p-value | r | p-value | r | p-value | |
ΔFVC | -0.043 | 0.466 | -0.142 | 0.438 | -0.033 | 0.637 | -0.031 | 0.828 |
ΔFVC % predicted | -0.047 | 0.432 | -0.187 | 0.540 | -0.033 | 0.632 | -0.014 | 0.922 |
ΔFEV1 | 0.061 | 0.294 | -0.115 | 0.529 | 0.008 | 0.907 | 0.240 | 0.090 |
ΔFEV1 % predicted | 0.059 | 0.332 | -0.215 | 0.481 | 0.029 | 0.680 | 0.269 | 0.056 |
ΔFEV1/FVC | 0.149 | 0.010* | 0.259 | 0.153 | 0.053 | 0.445 | 0.326 | 0.019* |